We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Flow Cytometry Assay Measures NK Cell Function

By LabMedica International staff writers
Posted on 13 May 2013
Peripheral blood natural killer (NK) cell function in healthy adults has been assessed using the target-induced NK loss (TINKL) assay.

The TINKL assay is a sensitive flow cytometry-based assay for measuring NK cell function; its clinical application has been evaluated and the activity measured, which is independent of the number of NK cells in the assay. More...


Immunologists at The Canberra Hospital (Garran, ACT, Australia) collected blood from 70 healthy adult male, and 53 healthy female volunteers. Their mean age (± standard deviation) was 38 ± 11 years, ranging from 19 to 65 years. Venous blood was collected in vacutainers containing ethylenediaminetetraacetic acid (EDTA), and samples were processed within 24 hours. Peripheral blood mononuclear cells (PBMC) were isolated, cryopreserved, and stored in liquid nitrogen. On the day prior to assay, PBMC were thawed and maintained in culture overnight.

The TINKL assay was conducted using NK-sensitive erythroleukaemic cell K562 was used to measure natural killing, and the NK-resistant Raji B lymphoblastoid cell in the presence of the CD20 monoclonal antibody Rituximab was used to measure antibody-dependent killing. Peripheral blood NK cell function measured by the TINKL assay was assessed in repeated samples of 123 healthy adults.

The PBMC were assayed in 21 trials over a three-month period. NK loss was 31% ± 10% (range 7% to 55%) as a consequence of natural killing, and 39% ± 10% (range 14% to 64%) as a consequence of antibody-dependent killing. The variation in NK cell function in the population measured by the TINKL assay is greater than can be accounted for by interexperimental variability. The intraexperimental coefficient of variation (CV) was on average 11% for natural killing and 3% for antibody-dependent killing, compared to 14% and 9% respectively for the interexperimental variation.

The authors concluded that their data provides additional information on the TINKL assay relevant to testing NK cell function in a clinical setting. The intra-experimental variability and the inter-experimental variability of the assay have been quantified, and the large range in NK cell function in a population of healthy donors is now chronicled. The study was published on April 6, 2013, in the Journal of Immunological Methods.

Related Links:
The Canberra Hospital


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Amoebiasis Test
ELI.H.A Amoeba
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.